Search
Dementia Clinical Trials in Los Angeles, CA
A listing of 11 Dementia clinical trials in Los Angeles, CA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 11 of 11
The city of Los Angeles, California, currently has 11 active clinical trials seeking participants for Dementia research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Salivary Biomarkers for People with Frontotemporal Dementia (FTD)
Recruiting
Participants for this study included anyone ages 45 to 85+ years of age with Frontotemporal Dementia (FTD). In this research study, you will be potentially required to give a saliva sample. This saliva sample will be obtained by a cotton pad being placed within the participant's mouth absorbing the saliva. In addition, Prior to the salivary collection, you will be potentially asked to take a general survey about your diagnosis and other health questions to verify if you fit the criteria for the study. The purpose of this study is to provide insight into how we can use the proteins Tau and TDP-43 can be used to identify Frontotemporal Dementia early. Another important aspect of this research is to create a non-invasive biomarker using saliva that can benefit the efficiency of identifying disease
Conditions:
Frontotemporal Dementia
Frontotemporal Degeneration
FTD
Frontotemporal Dementia (FTD)
Frontal Temporal Dementia (FTD)
Featured Trial
High blood pressure (Hypertension) Trials
Recruiting
High blood pressure (Hypertension) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
High blood pressure (Hypertension)
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: University of California, Los Angeles, Los Angeles, California +1 locations
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Recruiting
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.
To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB.
Clinicians use the C... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/18/2024
Locations: Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California
Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Recruiting
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/10/2024
Locations: USC Keck School of Medicine, Los Angeles, California
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/30/2024
Locations: Clinical Research Site #840-004, Los Angeles, California +1 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
North American Prodromal Synucleinopathy Consortium Stage 2
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss.
Ag... Read More
Gender:
All
Ages:
Between 60 years and 90 years
Trial Updated:
02/27/2024
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Cognitive Impairment, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Recruiting
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2024
Locations: USC Keck School of Medicine, Los Angeles, California
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
01/16/2024
Locations: Mary S Easton Center for Alzheimer's Research and Care UCLA, Los Angeles, California
Conditions: Agitation, Alzheimer's Type Dementia
Trial of Parkinson's And Zoledronic Acid
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
1 - 11 of 11